The surge in aging population globally and awareness regarding the advantages of orthobiologic therapies is fueling the orthobiologics market size. Rise in prevalence of musculoskeletal disorders and sports injuries is driving demand for orthobiologic treatments.
Osteoarthritis, a common musculoskeletal condition, affects a significant portion of the population. While arthritis is more prevalent among older adults, it can also affect younger individuals, including athletes and those who experience joint injuries or trauma.
Advancements in regenerative medicine and biotechnology have led to the development of innovative orthobiologic products with various effective combinations, attracting substantial investments and research endeavors in the field.
Furthermore, favorable reimbursement policies and government initiatives aimed at enhancing healthcare infrastructure have propelled the orthobiologics market growth by improving patient access to orthobiologic treatments.
The orthobiologics market comprises a wide range of biological materials and substances utilized in orthopedic procedures aimed at facilitating bone healing, regeneration, and repair.
They encompass bone grafts, growth factors, and stem cell therapy, primarily focusing on addressing musculoskeletal conditions such as fractures, osteoarthritis, spinal fusion, and sports injuries.
These products derived from natural sources such as bone, cartilage, or blood, or synthesized using biotechnology methods, are engineered to enhance the body's natural healing processes by stimulating tissue growth, mitigating inflammation, and enhancing overall bone health.
While orthobiologic therapies have gained popularity in orthopedic surgery as potential treatments for managing musculoskeletal conditions, the market for these products currently lacks regulation by the Food and Drug Administration (FDA), resulting in a plethora of available yet untested options.
The new innovative orthobiologic products have revolutionized orthopedics, offering less invasive treatment alternatives and yielding improved patient outcomes. Advancements include the development of novel biomaterials such as synthetic bone graft substitutes, along with injectable biologics including platelet-rich plasma (PRP) and hyaluronic acid derivatives.
Furthermore, biological agents such as growth factors and cytokines are being harnessed to promote bone formation and expedite healing in orthopedic surgeries.
| Attribute | Detail |
|---|---|
| Drivers |
|
The past few years have seen a notable surge in demand for minimally invasive procedures or options such as orthobiologics among both patients and healthcare providers. These procedures offer numerous advantages over traditional surgical methods, including shorter recovery periods, decreased pain, and fewer complications.
Within the realm of orthopedic surgery, minimally invasive techniques have gained prominence, with orthobiologics playing a pivotal role in driving this trend. This is offering lucrative orthobiologics market opportunities.
Orthobiologics, comprising biological substances including stem cells, growth factors, and other biologic materials, are integral to orthopedic surgery and treatment.
These substances find application in minimally invasive procedures such as arthroscopy, a technique involving the insertion of a small camera and instruments into the joint through minor incisions. Arthroscopy is commonly used for the diagnosis and treatment of various joint issues, including arthritis, ligament injuries, and cartilage damage.
As per the orthobiologics market report, platelet-rich plasma (PRP) therapy has been shown to significantly alleviate pain and enhance function in patients with knee osteoarthritis, contributing to its growing popularity.
BMAC, a form of regenerative medicine, entails extracting a small amount of bone marrow from a patient's hip bone, processing it, and subsequently injecting it into the fracture site to foster bone healing and restore normal function.
This procedure, performed using minimally invasive techniques, has demonstrated remarkable efficacy in accelerating bone healing and diminishing the necessity for additional surgical interventions.
Sports injuries, ranging from mild strains and sprains to more severe injuries such as fractures and ligament tears are a common occurrence among athletes and individuals who engage in physical activities. Orthobiologics has emerged as a promising treatment option for sports injuries.
According to a report by the American Academy of Orthopaedic Surgeons (AAOS), sports injuries account for around 8.6 million visits to emergency departments in the U.S. each year. These injuries can be caused by a range of factors, including overuse, poor technique, and accidents.
The National Safety Council (NSC) reported that sports-related injuries are the second leading cause of emergency department visits for children and adolescents aged 5-19 years in the U.S.
The most common types of sports injury are sprains and strains, which account for about 40% of all sports injuries. Fractures make up about 10% of all sports injuries. Thus the surge in incidence of sports injuries is expected to propel the orthobiologics market growth.
As per the orthobiologics market analysis, in terms of product, hyaluronic acid (HA) has emerged as the major market segment in the field of orthobiologics.
For decades, HA has been widely utilized as a viscosupplement in the treatment of knee osteoarthritis. Its capacity to lubricate the joints, augment lubricant levels, and decrease inflammation through biochemical processes has made it the standard of care in knee OA treatment.
It has also shown transient benefits in pain relief and improved range of motion. Viscosupplementation, which comprises hyaluronic acid injections, was the first generation of orthobiologics.
Based on end-user, the orthobiologics market segmentation includes hospitals, orthopedic clinics, and others.
Hospitals accounted for highest market share as they have a multidisciplinary approach. Hospitals have a large and growing patient base, which increases the demand for orthopedic procedures and the use of orthobiologics.
Furthermore, hospitals are typically well-equipped to handle the storage and handling requirements of orthobiologics, which are often temperature-sensitive and require specialized handling procedures.
Hospitals offer all treatment modalities under one roof, ensuring seamless coordination and continuity of care for patients.
| Attribute | Detail |
|---|---|
| Leading Region | Europe |
According to the latest orthobiologics market forecast, Europe holds a substantial share in the global landscape. Europe is witnessing rapid population aging. According to Arthritis Europe, over 180 million individuals in Europe are currently affected with osteoarthritis.
This growing patient demographic fuels the demand for innovative treatments such as stem cell therapy, alternative bone transplant methods, and bioactive coatings on implants to facilitate bone repair.
Key countries in Europe are investing significantly in biomedical research, indicating a prospective expansion in the utilization of orthobiologics in the coming years.
India presents a substantial patient pool for osteoarthritis (OA), given the rapid increase in the geriatric population. According to surveys, India has a comparatively higher worldwide prevalence of proliferative osteoarthritis (OA), with knee osteoarthritis affecting 22%-39% of the population.
OA alone impacts over 50 million Indians. Additionally, factors such as lifestyle changes, sports injuries, and a surge in number of accidents in the country contribute to increased awareness and adoption of orthobiologics, thus fueling market progress.
Major players in the pharmaceutical industry are engaging in mergers, expansions, and investing in innovative products, which bodes well for the orthobiologics market.
For instance, Orthofix and SeaSpine merged in January 2023, forming a global spine and orthopedics company boasting a comprehensive portfolio spanning biologics, spinal hardware, bone growth therapies, specialized orthopedic solutions, and a surgical navigation system.
The global orthobiologics market share is fragmented with the presence of a number of players. Arthrex, Inc., ATEC Spine, Inc., Bioventus, Exactech, Inc., Globus Medical, Integra Lifesciences Corporation, Johnson & Johnson, Medtronic plc, MTF Biologics, NORAKER, RTI Surgical, Stryker, and Zimmer Biomet are the prominent orthobiologics industry manufacturers.
Key players have been profiled in the orthobiologics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 6.2 Bn |
| Forecast Value in 2031 | More than US$ 10.3 Bn |
| Growth Rate (CAGR) | 5.7% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Orthobiologics Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
It was valued at US$ 6.2 Bn in 2022
It is projected to reach more than US$ 10.3 Bn by the end of 2031
The CAGR is anticipated to be 5.7% from 2023 to 2031
Europe is expected to account for largest share from 2023 to 2031
Arthrex, Inc., ATEC Spine, Inc., Bioventus, Exactech, Inc., Globus Medical, Integra Lifesciences Corporation, Johnson & Johnson, Medtronic plc, MTF Biologics, NORAKER, RTI Surgical, Stryker, and Zimmer Biomet
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Orthobiologics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Orthobiologics Market Analysis and Forecasts, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements in Orthobiologics
5.2. Incidence of Orthopedic Disorders
5.3. Regulatory Scenario, by Key Countries
5.4. Reimbursement Scenario, by Key Countries
5.5. Pricing Analysis of Orthobiologics
5.6. Pipeline Analysis
5.7. Overview of Most Effective Combinations of Orthobiologics products
5.8. COVID-19 Pandemic Impact Analysis
6. Global Orthobiologics Market Analysis and Forecasts, By Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Product, 2017-2031
6.3.1. Demineralized Bone Matrix (DBM)
6.3.2. Hydroxyapatite (HAp)
6.3.3. Hyaluronic acid (HA)
6.3.4. Calcium Sulfate Matrix
6.3.5. β-tricalcium phosphate (β-TCP)
6.3.6. β-TCP + HAp
6.3.7. DBM + PLGA
6.3.8. Regenerative Medicine
6.3.8.1. PRP
6.3.8.2. BMAC
6.3.8.3. SVF
6.3.8.4. Others (Exosome, etc.)
6.3.9. Growth Factors
6.3.9.1. BMP2
6.3.9.2. FGF2
6.3.9.3. TGF beta
6.3.9.4. VEGF
6.3.9.5. Others (IGF, etc.)
6.4. Market Attractiveness By Product
7. Global Orthobiologics Market Analysis and Forecasts, By End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By End-user, 2017-2031
7.3.1. Hospitals
7.3.2. Orthopedic Clinics
7.3.3. Others (ENT Clinics, etc.)
7.4. Market Attractiveness By End-user
8. Global Orthobiologics Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. Europe
8.2.2. India
8.2.3. Rest of the World
8.3. Market Attractiveness By Country/Region
9. Europe Orthobiologics Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast By Product, 2017-2031
9.2.1. Demineralized Bone Matrix (DBM)
9.2.2. Hydroxyapatite (HAp)
9.2.3. Hyaluronic acid (HA)
9.2.4. Calcium Sulfate Matrix
9.2.5. β-tricalcium phosphate (β-TCP)
9.2.6. β-TCP + Hap
9.2.7. DBM + PLGA
9.2.8. β-TCP + PLGA
9.2.9. Regenerative Medicine
9.2.9.1. PRP
9.2.9.2. BMAC
9.2.9.3. SVF
9.2.9.4. Others (Exosome, etc.)
9.2.10. Growth Factors
9.2.10.1. BMP2
9.2.10.2. FGF2
9.2.10.3. TGF beta
9.2.10.4. VEGF
9.2.10.5. Others (IGF, etc.)
9.3. Market Value Forecast By End-user, 2017-2031
9.3.1. Hospitals
9.3.2. Orthopedic Clinics
9.3.3. Others (ENT Clinics, etc.)
9.4. Market Value Forecast By Country, 2017-2031
9.4.1. Germany
9.4.2. U.K.
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Rest of Europe
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By End-user
9.5.3. By Country
10. India Orthobiologics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Product, 2017-2031
10.2.1. Demineralized Bone Matrix (DBM)
10.2.2. Hydroxyapatite (HAp)
10.2.3. Hyaluronic acid (HA)
10.2.4. Calcium Sulfate Matrix
10.2.5. β-tricalcium phosphate (β-TCP)
10.2.6. β-TCP + HAp
10.2.7. DBM + PLGA
10.2.8. β-TCP + PLGA
10.2.9. Regenerative Medicine
10.2.9.1. PRP
10.2.9.2. BMAC
10.2.9.3. SVF
10.2.9.4. Others (Exosome, etc.)
10.2.10. Growth Factors
10.2.10.1. BMP2
10.2.10.2. FGF2
10.2.10.3. TGF beta
10.2.10.4. VEGF
10.2.10.5. Others (IGF, etc.)
10.3. Market Value Forecast By End-user, 2017-2031
10.3.1. Hospitals
10.3.2. Orthopedic Clinics
10.3.3. Others (ENT Clinics, etc.)
10.4. Market Attractiveness Analysis
10.4.1. By Product
10.4.2. By End-user
11. Rest of the World Orthobiologics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Product, 2017-2031
11.2.1. Demineralized Bone Matrix (DBM)
11.2.2. Hydroxyapatite (HAp)
11.2.3. Hyaluronic acid (HA)
11.2.4. Calcium Sulfate Matrix
11.2.5. β-tricalcium phosphate (β-TCP)
11.2.6. β-TCP + HAp
11.2.7. DBM + PLGA
11.2.8. β-TCP + PLGA
11.2.9. Regenerative Medicine
11.2.9.1. PRP
11.2.9.2. BMAC
11.2.9.3. SVF
11.2.9.4. Others (Exosome, etc.)
11.2.10. Growth Factors
11.2.10.1. BMP2
11.2.10.2. FGF2
11.2.10.3. TGF beta
11.2.10.4. VEGF
11.2.10.5. Others (IGF, etc.)
11.3. Market Value Forecast By End-user, 2017-2031
11.3.1. Hospitals
11.3.2. Orthopedic Clinics
11.3.3. Others (ENT Clinics, etc.)
11.4. Market Attractiveness Analysis
11.4.1. By Product
11.4.2. By End-user
12. Competition Landscape
12.1. Market Player - Competition Matrix (By Tier and Size of companies)
12.2. Market Share Analysis By Company (2022)
12.3. Company Profiles
12.3.1. Arthrex, Inc.
12.3.1.1. Company Overview
12.3.1.2. Financial Overview
12.3.1.3. Product Portfolio
12.3.1.4. Business Strategies
12.3.1.5. Recent Developments
12.3.2. ATEC Spine, Inc.
12.3.2.1. Company Overview
12.3.2.2. Financial Overview
12.3.2.3. Product Portfolio
12.3.2.4. Business Strategies
12.3.2.5. Recent Developments
12.3.3. Bioventus
12.3.3.1. Company Overview
12.3.3.2. Financial Overview
12.3.3.3. Product Portfolio
12.3.3.4. Business Strategies
12.3.3.5. Recent Developments
12.3.4. Exactech, Inc.
12.3.4.1. Company Overview
12.3.4.2. Financial Overview
12.3.4.3. Product Portfolio
12.3.4.4. Business Strategies
12.3.4.5. Recent Developments
12.3.5. Globus Medical
12.3.5.1. Company Overview
12.3.5.2. Financial Overview
12.3.5.3. Product Portfolio
12.3.5.4. Business Strategies
12.3.5.5. Recent Developments
12.3.6. Integra Lifesciences Corporation
12.3.6.1. Company Overview
12.3.6.2. Financial Overview
12.3.6.3. Product Portfolio
12.3.6.4. Business Strategies
12.3.6.5. Recent Developments
12.3.7. Johnson & Johnson
12.3.7.1. Company Overview
12.3.7.2. Financial Overview
12.3.7.3. Product Portfolio
12.3.7.4. Business Strategies
12.3.7.5. Recent Developments
12.3.8. Medtronic plc
12.3.8.1. Company Overview
12.3.8.2. Financial Overview
12.3.8.3. Product Portfolio
12.3.8.4. Business Strategies
12.3.8.5. Recent Developments
12.3.9. MTF Biologics
12.3.9.1. Company Overview
12.3.9.2. Financial Overview
12.3.9.3. Product Portfolio
12.3.9.4. Business Strategies
12.3.9.5. Recent Developments
12.3.10. NORAKER
12.3.10.1. Company Overview
12.3.10.2. Financial Overview
12.3.10.3. Product Portfolio
12.3.10.4. Business Strategies
12.3.10.5. Recent Developments
12.3.11. RTI Surgical
12.3.11.1. Company Overview
12.3.11.2. Financial Overview
12.3.11.3. Product Portfolio
12.3.11.4. Business Strategies
12.3.11.5. Recent Developments
12.3.12. Stryker
12.3.12.1. Company Overview
12.3.12.2. Financial Overview
12.3.12.3. Product Portfolio
12.3.12.4. Business Strategies
12.3.12.5. Recent Developments
12.3.13. Zimmer Biomet
12.3.13.1. Company Overview
12.3.13.2. Financial Overview
12.3.13.3. Product Portfolio
12.3.13.4. Business Strategies
12.3.13.5. Recent Developments
List of Tables
Table 01: Global Orthobiologics Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 02: Global Orthobiologics Market Value (US$ Mn) Forecast, by Regenerative Medicine, 2017-2031
Table 03: Global Orthobiologics Market Value (US$ Mn) Forecast, by Growth Factors, 2017-2031
Table 04: Global Orthobiologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 05: Global Orthobiologics Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: India Orthobiologics Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 07: India Orthobiologics Market Value (US$ Mn) Forecast, by Regenerative Medicine, 2017-2031
Table 08: India Orthobiologics Market Value (US$ Mn) Forecast, by Growth Factors, 2017-2031
Table 09: India Orthobiologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 10: Europe Orthobiologics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 11: Europe Orthobiologics Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 12: Europe Orthobiologics Market Value (US$ Mn) Forecast, by Regenerative Medicine, 2017-2031
Table 13: Europe Orthobiologics Market Value (US$ Mn) Forecast, by Growth Factors, 2017-2031
Table 14: Europe Orthobiologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 15: Rest of the World Orthobiologics Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 16: Rest of the World Orthobiologics Market Value (US$ Mn) Forecast, by Regenerative Medicine, 2017-2031
Table 17: Rest of the World Orthobiologics Market Value (US$ Mn) Forecast, by Growth Factors, 2017-2031
Table 18: Rest of the World Orthobiologics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global Orthobiologics Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Orthobiologics Market Share Analysis, by Product, 2022
Figure 03: Global Orthobiologics Market Share Analysis, by End-user, 2022
Figure 04: Global Orthobiologics Market Value (US$ Mn) Share Analysis, by Product, 2022 and 2031
Figure 05: Global Orthobiologics Market Share Analysis, by Product, 2022
Figure 06: Global Orthobiologics Market Share Analysis, by Product, 2031
Figure 07: Global Orthobiologics Market Attractiveness Analysis, by Product, 2023-2031
Figure 08: Global Orthobiologics Market Revenue (US$ Mn), by Demineralized Bone Matrix (DBM), 2017-2031
Figure 09: Global Orthobiologics Market Value Share Analysis, by Demineralized Bone Matrix (DBM), 2022 and 2031
Figure 10: Global Orthobiologics Market Revenue (US$ Mn), by Hydroxyapatite (HAp), 2017-2031
Figure 11: Global Orthobiologics Market Value Share Analysis, by Hydroxyapatite (HAp), 2022 and 2031
Figure 12: Global Orthobiologics Market Revenue (US$ Mn), by Hyaluronic acid (HA), 2017-2031
Figure 13: Global Orthobiologics Market Value Share Analysis, by Hyaluronic acid (HA), 2022 and 2031
Figure 14: Global Orthobiologics Market Revenue (US$ Mn), by Calcium Sulfate Matrix, 2017-2031
Figure 15: Global Orthobiologics Market Value Share Analysis, by Calcium Sulfate Matrix, 2022 and 2031
Figure 16: Global Orthobiologics Market Revenue (US$ Mn), by β-tricalcium phosphate (β-TCP), 2017-2031
Figure 17: Global Orthobiologics Market Value Share Analysis, by β-tricalcium phosphate (β-TCP), 2022 and 2031
Figure 18: Global Orthobiologics Market Revenue (US$ Mn), by β-TCP + HAp, 2017-2031
Figure 19: Global Orthobiologics Market Value Share Analysis, by β-TCP + HAp, 2022 and 2031
Figure 20: Global Orthobiologics Market Revenue (US$ Mn), by DBM + HA, 2017-2031
Figure 21: Global Orthobiologics Market Value Share Analysis, by DBM + HA, 2022 and 2031
Figure 22: Global Orthobiologics Market Revenue (US$ Mn), by β-TCP + PLGA, 2017-2031
Figure 23: Global Orthobiologics Market Value Share Analysis, by β-TCP + PLGA, 2022 and 2031
Figure 24: Global Orthobiologics Market Revenue (US$ Mn), by Regenerative medicine, 2017-2031
Figure 25: Global Orthobiologics Market Value Share Analysis, by Regenerative medicine, 2022 and 2031
Figure 26: Global Orthobiologics Market Revenue (US$ Mn), by Growth Factors, 2017-2031
Figure 27: Global Orthobiologics Market Value Share Analysis, by Growth Factors, 2022 and 2031
Figure 28: Global Orthobiologics Market Value (US$ Mn) Share Analysis, by End-user, 2022 and 2031
Figure 29: Global Orthobiologics Market Share Analysis, by End-user, 2022
Figure 30: Global Orthobiologics Market Share Analysis, by End-user, 2031
Figure 31: Global Orthobiologics Market Revenue (US$ Mn), by Hospitals, 2017-2031
Figure 32: Global Orthobiologics Market Value Share Analysis, by Hospitals, 2022 and 2031
Figure 33: Global Orthobiologics Market Revenue (US$ Mn), by Orthopedic Clinics, 2017-2031
Figure 34: Global Orthobiologics Market Value Share Analysis, by Orthopedic Clinics, 2022 and 2031
Figure 35: Global Orthobiologics Market Revenue (US$ Mn), by Others, 2017-2031
Figure 36: Global Orthobiologics Market Value Share Analysis, by Others, 2022 and 2031
Figure 37: Global Orthobiologics Market Value Share Analysis, by Region, 2022 and 2031
Figure 38: Global Orthobiologics Market Attractiveness Analysis, by Region, 2023-2031
Figure 39: India Orthobiologics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 40: India Orthobiologics Market Value Share Analysis, by Product, 2022 and 2031
Figure 41: India Orthobiologics Market Attractiveness Analysis, Product, 2023-2031
Figure 42: India Orthobiologics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 43: India Orthobiologics Market Attractiveness Analysis, End-user, 2023-2031
Figure 44: Europe Orthobiologics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 45: Europe Orthobiologics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 46: Europe Orthobiologics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 47: Europe Orthobiologics Market Value Share Analysis, by Product, 2022 and 2031
Figure 48: Europe Orthobiologics Market Attractiveness Analysis, Product, 2023-2031
Figure 49: Europe Orthobiologics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 50: Europe Orthobiologics Market Attractiveness Analysis, End-user, 2023-2031
Figure 51: Rest of the World Orthobiologics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017-2031
Figure 52: Rest of the World Orthobiologics Market Value Share Analysis, by Product, 2022 and 2031
Figure 53: Rest of the World Orthobiologics Market Attractiveness Analysis, Product, 2023-2031
Figure 54: Rest of the World Orthobiologics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 55: Rest of the World Orthobiologics Market Attractiveness Analysis, End-user, 2023-2031
Figure 56: Market Share Analysis by Company (2022)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Orthobiologics Market
*86 figures and 60 tables includes